COMP

COMP

COMP 詳細

Molecule Name
Sodium channel protein type VIII alpha subunit
分子の別称
COMP,TSP5,EDM1,EPD1,MED,PSACH,THBS5
Drug Development Progress
治験薬の数4
市販薬剤の数1
研究&開発段階Approved
ターゲットの別称
Sodium Channel, Voltage Gated, Type VIII Alpha Subunit,Voltage-Gated Sodium Channel Type VIII Alpha Protein,HNa6/Scn8a Voltage-Gated Sodium Channel,CERIII,EIEE13,Nav1.6,BFIS5,NaCh6,CIAT,PN4,NAV1.6 Voltage-Gated Sodium Channel,MYOCL2,Sodium channel protein type 8 subunit alpha,Sodium channel protein type VIII subunit alpha,MED,SCN8A,Sodium Voltage-Gated Channel Alpha Subunit 8,Sodium Channel, Voltage Gated, Type VIII, Alpha Subunit,Voltage-Gated Sodium Channel Subunit Alpha Nav1.6,Sodium Channel, Voltage Gated, Type VIII, Alpha Polypeptide
バックグランド
Cartilage oligomeric matrix protein (COMP) is also known as Thrombospondin-5 (TSP5), EDM1, EPD1, MED, PSACH, THBS5, which belongs to the thrombospondin family. COMP / TSP5 contains 4 EGF-like domains, 1 TSP C-terminal (TSPC) domain, 8 TSP type-3 repeats. Abundantly expressed in the chondrocyte extracellular matrix, and is also found in bone, tendon, ligament and synovium and blood vessels. COMP may play a role in the structural integrity of cartilage via its interaction with other extracellular matrix proteins such as the collagens and fibronectin. COMP can mediate the interaction of chondrocytes with the cartilage extracellular matrix through interaction with cell surface integrin receptors. Thrombospondin-5 could play a role in the pathogenesis of osteoarthritis. COMP is a marker of cartilage turnover.

COMP 製品リスト

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
PRAX-562PRAX-562Phase 3 ClinicalPraxis Precision Medicines
Brain Diseases; Epilepsy
詳細
XEN-901NBI-921352; XEN-901Phase 2 ClinicalXenon Pharma
Epilepsies, Partial; Brain Diseases; Epilepsy
詳細
PRAX-330GS-458967; GS-967; PRAX-330Phase 1 ClinicalPraxis Precision Medicines Inc
Epilepsy
詳細
NBI-355NBI-355Phase 1 ClinicalNeurocrine Biosciences Inc
Epilepsy
詳細

市販薬剤に関する情報

英語名研究コード研究開発ステージ会社オリジナル製品名最初に承認をした国最初の適応症最初に承認を受けた会社承認された日付適応症臨床試験
Pirmenol HydrochlorideCI-845ApprovedSumitomo Dainippon, Pfizer IncPimavar, PimenolJapanArrhythmias, Cardiacnull1994-01-01
Arrhythmias, Cardiac
詳細